Moderna

The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.

New COVID-19 boosters targeting recent strains like KP.2 were approved, aiming to enhance protection as fall approaches. Despite delays in vaccine shipments to some pharmacies, experts urge getting the booster and flu vaccine by October. High-risk individuals are especially encouraged to vaccinate early, with strategies like mask-wearing recommended for those awaiting vaccination.

CoherentMI's report on the RNA Therapeutics Market projects it to grow from US$2.5M in 2024 to US$948M by 2031, at a CAGR of 68%. The market leverages RNA interference and antisense technologies for gene expression modulation, targeting hereditary disorders, cancer, and infectious diseases. Key players include Alphavax, Arcturus Therapeutics, Atyr Pharma, and Gritstone Bio. The market is driven by increasing R&D investments and demand for precision medicine.

Moderna's Laval, Quebec facility granted Drug Establishment License by Health Canada, enabling mRNA vaccine production in Canada by 2025, including COVID-19, RSV, and seasonal influenza vaccines.

The Basel Area is a leading European hub for life sciences and biotech, attracting major companies like Roche and Novartis. Its appeal lies in a rich ecosystem of research, talent, and infrastructure, making it a prime location for innovation and growth in the sector.

Newly updated COVID-19 vaccines, including mRNA vaccines from Moderna and Pfizer-BioNTech and the Novavax protein-based vaccine, are available across the U.S. The CDC recommends everyone age 6 months and older receive the updated vaccine, which targets the KP.2 strain of COVID-19. Vaccines offer protection against severe illness, hospitalization, and death, and help prevent long COVID. Individuals at higher risk, such as the elderly and immunocompromised, should get vaccinated promptly. The vaccine is free for those with insurance and through certain programs for uninsured individuals and children.

Rosen Law Firm filed a class action lawsuit on behalf of Moderna, Inc. (NASDAQ: MRNA) securities purchasers between January 18, 2023, and June 25, 2024. The lawsuit alleges false and misleading statements regarding mRNA-1345's effectiveness. Lead plaintiff deadline is October 8, 2024.

Lykos Therapeutics reshuffles senior management after FDA rejection of MDMA-AT for PTSD, appointing Michael Mullette as interim CEO and Dr. David Hough as CMO. The company focuses on regulatory engagement and clinical development, with Mullette and Hough bringing extensive pharma experience. Amy Emerson steps down as CEO, transitioning to an advisory role, marking Lykos' shift from its MAPS roots towards medicalizing MDMA.

ArtLifting, founded by Liz and Spencer Powers, brokers art by disadvantaged artists, earning them $6.5 million. Their works, including by Allen Chamberland and Lisa Murphy, are displayed in corporate offices, including Moderna and Foundation Medicine, aiming to break stigmas and provide income.